Polymeric material for accommodating intraocular lenses

Abstract
The disclosure relates generally to a polymeric material for use in accommodating intraocular lenses for implantation in a lens chamber of a subject's eye. The present disclosure is directed to a polymeric material which comprises a fluorosilicone polymer and a silica component. The presently disclosed polymeric material is both optically clear and has a sufficiently low Young's modulus such that it can effectively respond to the eye's natural accommodative forces and thus can be used in accommodating intraocular lenses. When used in the fabrication of an intraocular lenses, the polymeric material disclosed herein protect the physical characteristics of the lens as the added hydrophobicity of the fluorosilicone polymer allows it to effectively resist diffusion of fluid from the eye and the adhesion of biologica materials.
Description
FIELD

The disclosure relates generally to a polymeric material for use in accommodating intraocular lenses for implantation in a lens chamber of a subject's eye.


BACKGROUND

Surgical procedures on the eye have been on the rise as technological advances permit for sophisticated interventions to address a wide variety of ophthalmic conditions. Patient acceptance has increased over the last twenty years as such procedures have proven to be generally safe and to produce results that significantly improve patient quality of life.


Cataract surgery remains one of the most common surgical procedures, with over 16 million cataract procedures being performed worldwide. It is expected that this number will continue to increase as average life expectancies continue to rise. Cataracts are typically treated by removing the crystalline lens from the eye and implanting an intraocular lens (“IOL”) in its place. As conventional IOL devices are primarily focused for distance visions, they fail to correct for presbyopia and reading glasses are still required. Thus, while patients who undergo a standard IOL implantation no longer experience clouding from cataracts, they are unable to accommodate, or change focus from near to far, from far to near, and to distances in between.


Surgeries to correct refractive errors of the eye have also become extremely common, of which LASIK enjoys substantial popularity with over 700,000 procedures being performed per year. Given the high prevalence of refractive errors and the relative safety and effectiveness of this procedure, more and more people are expected to turn to LASIK or other surgical procedures over conventional eyeglasses or contact lenses. Despite the success of LASIK in treating myopia, there remains an unmet need for an effective surgical intervention to correct for presbyopia, which cannot be treated by conventional LASIK procedures.


As nearly every cataract patient also suffers from presbyopia, there is convergence of market demands for the treatment of both these conditions. While there is a general acceptance among physicians and patients of having implantable intraocular lens in the treatment of cataracts, similar procedures to correct for presbyopia represent only 5% of the U.S. cataract market. There is therefore a need to address both ophthalmic cataracts and/or presbyopia in the growing aging population.


SUMMARY

The present disclosure is directed to a polymeric material which comprises a fluorosilicone polymer and a silica component. The presently disclosed polymeric material is both optically clear and has a sufficiently low Young's modulus such that it can effectively respond to the eye's natural accommodative forces and thus can be used in accommodating intraocular lenses. When used in the fabrication of an intraocular lenses, the polymeric material disclosed herein protect the physical characteristics of the lens as the added hydrophobicity of the fluorosilicone polymer allows it to effectively resist diffusion of fluid from the eye and the adhesion of biological materials.


Accordingly, in one aspect, provided herein is a polymeric material comprising a fluorosilicone polymer and up to about 30 weight % of a silica component, wherein the silica component has a surface area of at least about 280 m2/g.


In another aspect, provided herein is an implantable intraocular lens (IOL) comprising a polymeric material comprising a fluorosilicone polymer and up to about 30 weight % of a silica component, wherein the silica component has a surface area of at least about 280 m2/g.


In still another aspect, provided herein is an intraocular lens (IOL) device comprising a fluorosilicone polymer and up to about 30 weight % of a silica component, wherein the silica component has a surface area of at least about 280 m2/g. In one aspect, the intraocular lens (IOL) device comprises


(a) a first lens comprised of a fluorosilicone polymer and up to about 30 weight % of a silica component, wherein the silica component has a surface area of at least about 280 m2/g having a first Young's modulus;


(b) a second lens in spaced relation to the first lens along a central optical axis; and


(c) a circumferential portion encircling the first and second lens, the circumferential portion comprising an outer peripheral edge;


wherein at least one of a portion of the second lens and a portion of the circumferential portion is made of a material having a second Young's modulus; and wherein the first Young's modulus is less than the second Young's modulus.


Other objects, features and advantages of the described embodiments will become apparent to those skilled in the art from the following detailed description. It is to be understood, however, that the detailed description and specific examples, while indicating various embodiments of the present invention, are given by way of illustration and not imitation. Many changes and modifications within the scope of the present invention may be made without departing from the spirit thereof, and the invention includes all such modifications.







DETAILED DESCRIPTION

Specific, non-limiting embodiments of the present invention will now be described with reference to the drawings. It should be understood that such embodiments are by way of example and are merely illustrative of but a small number of embodiments within the scope of the present invention. Various changes and modifications obvious to one skilled in the art to which the present invention pertains are deemed to be within the spirit, scope and contemplation of the present invention as further defined in the appended claims.


Polymeric Material


The present disclosure is directed to a polymeric material comprising a fluorosilicone polymer and a silica component which is both optically clear and has a sufficiently low modulus such that it can effectively respond to the eye's natural accommodative forces and thus be used in accommodating intraocular lenses.


In one embodiment, the presently disclosed polymeric material comprises a fluorosilicone polymer and up to about 30 weight % of a silica component. The fluorosilicone polymer described herein is a crosslinked copolymer of dialkyl, diphenyl or phenylalkyl siloxane and a fluorinated dialkyl siloxane. Typically, the fluorosilicone polymer is a crosslinked copolymer of dialkyl, diphenyl or phenylalkyl siloxane and trifluoroalkyl(alkyl)siloxane, but can be a terpolymer or higher order polymer of diphenyl and/or phenylalkyl siloxane, dialkyl siloxane and trifluoroalkyl(alkyl)siloxane. In certain embodiments, the fluorosilicone polymer is a crosslinked copolymer of dialkyl siloxane, such as dimethyl siloxane, and trifluoroalkyl(alkyl)siloxane, such as 3,3,3-trifluoropropylmethyl siloxane. The ratio of dialkyl siloxane and trifluoroalkyl(alkyl)siloxane can be adjusted to tune the physical properties of the fluorosilicone polymer. For example, increasing the trifluoroalkyl(alkyl)siloxane can increase the hydrophobicity of the resulting fluorosilicone polymer. In some embodiments, the fluorosilicone polymer typically comprises at least about 25 mole % trifluoroalkyl(alkyl)siloxane, or about 25 mole % trifluoroalkyl(alkyl)siloxane, or about 30 mole % trifluoroalkyl(alkyl)siloxane, or about 35 mole % trifluoroalkyl(alkyl)siloxane, or about 40 mole % trifluoroalkyl(alkyl)siloxane, or about 50 mole % trifluoroalkyl(alkyl)siloxane or from about 25 mole % to about 50 mole %, or from about 25 mole % to about 40 mole % trifluoroalkyl(alkyl)siloxane.


In one embodiment, the fluorosilicone polymer is represented by formula (I):




embedded image



wherein:


n and m are each independently 0 to about 500;


t is about 100 to about 1000;


each R1 is independently alkyl or aryl;


R2 is haloalkyl;


R3 is alkyl or haloalkyl;


R4 and R5 are independently alkyl, haloalkyl or aryl; and


each X is a crosslinker which links the polymer of formula (I) with a second polymer of formula (I).


In one embodiment, n is about 50, or about 100, or about 125, or about 150, or about 200, or about 250, or about 300, or about 350, or about 400, or about 450, or about 500. In one embodiment, m is about 50, or about 100, or about 125, or about 150, or about 200, or about 250, or about 300, or about 350, or about 400, or about 450, or about 500. In another embodiment, n is about 100, and m is about 150.


In any embodiment, t is about 100, or about 125, or about 150, or about 200, or about 250, or about 300, or about 350, or about 400, or about 450, or about 500, or about 550, or about 600, or about 650, or about 700, or about 750, or about 800, or about 850, or about 900, or about 950, or about 1000.


In one embodiment, each R1 is alkyl. Suitable alkyl groups include, but are not limited to, C1-C6 alkyl groups such as methyl, ethyl, n-propyl, i-propyl, n-butyl, t-butyl, n-pentyl, n-hexyl, and the like. In another embodiment, each R1 is methyl. In one embodiment, R3 is alkyl, such as defined for R1. In another embodiment, R3 is methyl. In one embodiment, R4 is alkyl, such as defined for R1. In another embodiment, R4 is methyl. In one embodiment, R5 is alkyl, such as defined for R1. In another embodiment, R5 is methyl. In yet another embodiment, R4 and R5 are methyl. In still another embodiment, the fluorosilicone polymer is represented by formula (IA):




embedded image


wherein:


n is from 1 to about 500;


m is from 0 to about 500;


t is about 100 to about 1000;


R2 is haloalkyl;


R3 is alkyl or haloalkyl; and


each X is a crosslinker which links the polymer of formula (IA) with a second polymer of formula (IA).


In one embodiment, R2 is a haloalkyl group comprising from 1 to 3 halo (provided at least one is fluoro) substituents. Exemplary haloalkyl groups include, but are not limited to, fluoromethyl, 2-fluorethyl, 2,2-difluoroethyl, and 3,3,3-trifluoropropyl. In one embodiment, R2 is 3,3,3-trifluoropropyl.


The crosslinker is typically a methylhydrosiloxane-dimethylsiloxane copolymer with a methyl-hydrogen content of from about 30 to about 70 mole %. In some embodiments, the crosslinker has a chain length of from about 5 to about 30 repeating Si units (i.e., degree of polymerization).


In certain embodiments, the polymeric material provided herein has a degree of polymerization of from about 200 to about 500, or from about 300 to about 500, or about 400, or about 450.


In order to be used as an intraocular lens material, the polymeric material described herein should be optically clear. However, the fluorosilicone polymer and the silica component are not index matched. Thus the optical properties of the polymeric material must be maintained as the modulus is increased. Advantageously, the optical properties of the presently disclosed polymeric material can be tuned independently from the modulus. Several different factors contribute to the optical properties of the polymeric material, including the amount and particle size of the silica component.


Since the refractive index of the fluorosilicone polymer is low, it is contemplated that the particle size of the silica component should be as small as possible in order to obtain superior optical characteristics. In certain embodiments, the polymeric material provided herein has a refractive index of from about 1.35 to about 1.40, or from about 1.37 to from about 1.39, or about 1.38. Accordingly, the silica component as used herein has a surface area of at least about 280 m2/g, or at least about 300 m2/g, or at least about 310 m2/g, or at least about 320 m2/g, or at least about 330 m2/g, or at least about 340 m2/g, or at least about 350 m2/g. In certain embodiments, the silica component has an average particle size of less than about 11 nanometers. Fumed silica having an average particle size of about 7 nanometers in diameter is particularly suitable because the small particle size does not interfere with the wavelength of visible light and contributes to an improved optical resolution in the cured composition. Commercial fumed silica with particle sizes as low as 7 nm are commercially available (e.g., CABOT and Sigma). Typically, the silica component is present in an amount up to about 30 weight %, or 27 weight %, or about 25 weight %, or about 23 weight %, or about 20 weight %, or from about 20 to about 30 weight %.


The silica component as used herein is fumed or “activated” silica, which has been treated with a silazane. The amount of silica component should be such that the polymeric material is sufficiently reinforced, yet remains optically clear. Suitable silazanes and methods for carrying out the fumed silica treatment include the in situ reaction of small particle size fumed silica and are well known in the art. In such reactions, the silazane (e.g., hexamethyldisilazane) readily reacts with the hydroxyl functionalities on fumed silica, forming a trimethylsiloxane coating on the silica surface. In certain embodiments, the polymeric material provided herein has a Young's modulus of from about 10 psi to about 150 psi, or from about 50 psi to about 100 psi, or about 70 psi.


Other physical characteristics of the polymeric material can be modulated as well. In certain embodiments, the polymeric material provided herein has a tensile strength of from about 500 psi to about 1200 psi, or from about 700 psi to about 1000 psi, or about 900 psi. In certain embodiments, the polymeric material provided herein has a percent elongation of from about 400% to about 1000%, or about 600%.


Also provided herein are methods for making the above-described polymeric material. In certain embodiments, the method comprises the steps of:


(a) combining a vinyl end-capped fluorosilicone polymer with up to about 30 weight % of a silica component, wherein the silica component has a surface area of at least about 280 m2/g, to obtain a fluorosilicone base composition;


(b) adding a crosslinking agent and a curing agent to the fluorosilicone base composition; and


(c) curing the fluorosilicone base composition to obtain the polymeric material.


The vinyl end-capped fluorosilicone polymer can be synthesized using known methods from commercially available starting materials or purchased from commercial sources. For example, a vinyl end-capped trifluoropropylmethylsiloxane—dimethylsiloxane copolymer having a molecular weight of about 25,000 to about 35,000—is commercially available from Gelest. Alternatively, the vinyl end-capped fluorosilicone polymercan be synthesized as described in Example 1, for example. Suitable starting materials include, but are not limited to, alkylsiloxanes (e.g., octamethylcyclotetrasiloxane), haloalkylsiloxanes (e.g., trifluoropropyltrimethylcyclosiloxane), and the like. Suitable vinyl endblockers include, but are not limited to, vinyl-endblocked dimethyl siloxane oligomer.


In one embodiment, the fluorosilicone polymer has a long chain length, having a molecular weight of greater than 35,000 daltons, or greater than 50,000 daltons and, or greater than 70,000 daltons are desired.


In one embodiment, the fluorosilicone polymer is a compound of formula (II):




embedded image


wherein:

    • n and m are each independently 0 to about 500;
    • t is from about 100 to about 1000;
    • each R1 is independently alkyl or aryl;
    • R2 is haloalkyl;
    • R3 is alkyl or haloalkyl; and
    • R4 and R5 are independently alkyl, haloalkyl or aryl.


The polymeric material described herein has a degree of crosslinking such that the material has a sufficiently low modulus to minimize any potential deformation caused by forces applied during its use as, for example, an accommodating intraocular lens, yet also be sufficiently solid as to minimize the permeation of the gel. In certain embodiments, the polymeric material is lightly crosslinked, having less than about 5 parts per hundred (pph) crosslinker, or less than about 4 pph, or less than about 2 pph, or less than about 1 pp, or about 1 pph. The crosslinker is typically a methylhydrosiloxane-dimethylsiloxane copolymer with a methyl-hydrogen content of from about 30 to about 70 mole %. In some embodiments, the crosslinker has a chain length of from about 5 to about 30 repeating Si units (i.e., degree of polymerization).


In one embodiment, the curing step comprises adding a platinum catalyst. The platinum group metal catalyst can be any of the compatible platinum group metal-containing catalysts known to catalyze the addition of silicone-hydrogen atoms to silicon-bonded vinyl radicals. Platinum group metal-containing catalysts can be any of the known forms which are compatible, such as platinic chloride, salts of platinum, chloroplatinic acid and various complexes, for example, silicone complexes with platinum metal-containing groups. The platinum group metal-containing catalyst can be used in any catalytic quantity, such as in an amount sufficient to provide at least about 0.1 ppm weight of platinum group metal (as elemental metal) based on the total weight of the composition. In certain embodiments, at least about 10 ppm, or at least about 20 ppm, or at least 30 ppm, or at least about 40 ppm by weight of platinum catalyst was used.


Implantable Intraocular Lens (IOL)


A device implanted in the eye naturally becomes exposed to the fluid in the eye and the fluid can, over time, diffuse through the device and have unintended and/or undesired effects on the physical characteristics of the device. Attempts have been made to coat ophthalmic devices with barrier layers to prevent such diffusion, but these procedures can be costly and time consuming. In addition, if an ophthalmic device contains a chamber or channel within the device which contains a fluid, there is a risk that that fluid can diffuse out of its fluid chamber and into the polymeric material. This results in a decrease in the amount of fluid that can be utilized by the IOL, as well as to possibly alter the physical characteristics of the polymeric material. Fluorocarbon-containing silicone monomers can enhance a polymer's resistance to the diffusion of fluid, and as such, the polymeric material described herein can be used in ophthalmic devices to resist the diffusion of fluid into or out of the device.


The IOLs can be fabricated from the disclosed polymeric material using known molding techniques, such as disposable or polished stainless steel mold, having a mold cavity in the shape required for the correct refraction of light for the material. In practice, the uncured fluorosilicone base composition is introduced into the mold cavity, in an amount dictated by considerations relating to the lens size, refractive power, and structure, and then cured. Several methods of molding the lens can be employed, including injection molding, liquid injection molding, compression molding, and transfer molding.


Intraocular Lens (IOL) Device


The presently disclosed intraocular lenses can be used in an intraocular device for implantation in a patent. Such devices are known in the art, and include, for example, those described in U.S. Pat. Nos. 7,662,180 and 7,875,661.


In certain embodiments, the presently disclosed intraocular lenses can be used as a power changing lens in a two-part accommodating IOL device in which the power changing lens and a primary lens are in sliding contact with one another within a lens chamber. In such systems, the power changing lens is sized and shaped to take on and respond to the radially-inward forces which are applied along the peripheral edge of the lens. In contrast, the primary lens does not participate in providing an accommodative response and thus is sized and shaped so as to avoid interfering or resisting the radial compressive forces that are applied to the power changing lens. This may be accomplished by controlling the relative diameters and thicknesses of the power changing lens and the primary lens to maximize the extent to which the radial compressive forces are applied onto the power changing lens and to minimize the extent to which these forces are applied onto the primary lens.


Accordingly, in one embodiment, provided herein is an intraocular lens (IOL) device comprising:


(a) a first lens comprised of the polymeric material as described herein having a first Young's modulus;


(b) a second lens in spaced relation to the first lens along a central optical axis; and


(c) a circumferential portion encircling the first and second lens, the circumferential portion comprising an outer peripheral edge;


wherein at least one of a portion of the second lens and a portion of the circumferential portion is made of a material having a second Young's modulus; and wherein the first Young's modulus is less than the second Young's modulus.


In practice, the first lens (i.e., the power changing lens) and the second lens (i.e., the primary lens) are in sliding contact with one another within a lens chamber. The lens chamber is filled with a fluid or gel having specific physical and chemical characteristics to enhance the range of refractive power provided by the IOL during accommodation. The fluid or gel is selected such that it cooperates with the power changing lens in providing a sufficient range of accommodation of up to at least 3 diopters, preferably up to at least 5 diopters, preferably up to at least 10 diopters and most preferably up to at least 15 diopters.


In addition, a lens comprised of the polymeric material described herein has a reduced likelihood of buckling in a patient from contact with the primary lens as the surface is significantly more oleophobic than other polymers typically used for IOLs.


In addition to use in an IOL, the polymeric material of the present disclosure can also be used in other ophthalmic devices such as, but not limited to, contact lenses, keratoprostheses, capsular bag extension rings, corneal inlays, corneal rings, or other ophthalmic devices. An exemplary alternative use would be in the field of breast implants, such that the polymers can be used as an exterior shell-like material to prevent leakage of an internal material.


EXAMPLES
Example 1

An exemplary polymeric material according to the present disclosure was prepared as follows.


Vinyl Endblocked 40 mole % Fluorosilicone Polymer


A vinyl endblocked 40 mole % fluorosilicone polymer for use in the fluorosilicone base was prepared as follows. 140 parts octamethylcyclotetrasiloxane (D4 cyclics), 100 parts trifluoropropyltrimethylcyclosiloxane (D3 fluorocyclics), 3.2 parts vinyl-endblocked dimethyl siloxane oligomer (vinyl endblocker), and 0.1 parts potassium siloxanolate catalyst were agitated in a polymerization vessel and heated to about 150° C. At 150° C., potassium siloxanolate catalyst was added to the polymerization vessel. Once polymerization was visually observed by an increased viscosity, polymerization was continued for about 3 hours.


After about 3 hours, the catalyst was de-activated by purging polymer with CO2 for 1 hour and the polymer exposed to reduced pressure (minimum of 27″ Hg vacuum) at a temperature of from about 150° C. to about 180° C. until the volatile content reached an amount below about 3%.


Fluorosilicone Base


100 parts of the vinyl endblocked 40 mole % fluorosilicone polymer, 9 parts hexamethyldisilizane (HMDZ) and 3 parts water were added to a mixing vessel (e.g., sigma blade mixer). Once mixed, 60 parts activated silica (Tokuyama QS-30C fumed silica) was added in multiple additions until the silica was fully mixed into the fluorosilicone polymer. The composition was mixed at 80° C. for about 30 minutes, at which time the mixing vessel was heated to about 150° C. for about 3 hours under vacuum.


After about 3 hours, the heat and vacuum were removed. While the fluorosilicone base was still hot, additional fluorosilicone polymer was slowly added to the polymerization vessel until the silica content was reduced to approximately 25 parts. The fluorosilicone base was then dispersed in chlorinated solvent (i.e., perchloroethylene) to approximately 30% solids content, filtered through 1 micron media filter and subjected to heat and vacuum to remove solvent.


Polymeric Material Comprising a Fluorosilicone Polymer


Equal parts of A and B (Table 1) were mixed together, vacuum de-aired, and press cured in an ASTM test slab mold for about 10 minutes at 302° F. Cured test slab was allowed to equilibrate at room temperature for a minimum of 3 hours.










TABLE 1





Part A
Part B







100 part fluorosilicone base
100 parts fluorosilicone base


5-15 ppm platinum catalyst
2 parts methyl hydrogen siloxane crosslinker



0.3 pph methyl vinyl cyclosilicone inhibitor









Mechanical properties of the fluorosilicone polymer are shown in Table 2. Surprisingly, the fluorosilicone polymer as described herein exhibits an enhanced tensile strength while maintaining a low modulus when compared to a non-fluorinated silicone polymer. In addition, it is contemplated that the fluorosilicone polymer described herein maintains a suitable optical clarity due to the low silica content.
















Fluorosilicone
Non-fluorinated



polymer
silicone polymer




















Durometer (Shore A)
20
20



Tensile strength
900 psi
475 psi



% elongation
600%
300%



100% modulus
 70 psi
 65 psi










The invention described and claimed herein is not to be limited in scope by the specific preferred embodiments disclosed herein, as these embodiments are intended as illustrations of several aspects of the invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims.

Claims
  • 1. A polymeric material comprising a fluorosilicone polymer and up to about 30 weight % of a silica component, wherein the silica component has a surface area of at least about 280 m2/g, and wherein the fluorosilicone polymer comprises a polymer of formula
  • 2. The polymeric material of claim 1, wherein the silica component has a surface area of from about 280 m2/g to about 350 m2/g.
  • 3. The polymeric material of claim 1, comprising about 20% to about 27% of the silica component.
  • 4. The polymeric material of claim 1, wherein the fluorosilicone polymer comprises a crosslinked copolymer of dialkyl, diphenyl or phenylalkyl siloxane and fluorinated dialkyl siloxane.
  • 5. The polymeric material of claim 1, wherein the fluorosilicone polymer comprises a crosslinked copolymer of diphenyl, phenylalkyl, or dialkyl siloxane and trifluoroalkyl(alkyl)siloxane.
  • 6. The polymeric material of claim 1, wherein R2 is 3,3,3-trifluoropropyl.
  • 7. The polymeric material of claim 6, comprising at least about 25 mole % trifluoropropyl content.
  • 8. The polymeric material of claim 1, having a refractive index of from about 1.35 to about 1.40.
  • 9. The polymeric material of claim 1, having a tensile strength of from about 500 psi to about 1200 psi.
  • 10. The polymeric material of claim 1, having a percent elongation of from about 400% to about 1000%.
  • 11. The polymeric material of claim 1, having a degree of polymerization of from about 200 to about 500.
  • 12. The polymeric material of claim 1, having a Young's modulus of from about 50 psi to about 100 psi.
  • 13. The polymeric material of claim 1, wherein the crosslinker is a methylhydrosiloxane-dimethylsiloxane copolymer.
  • 14. The polymeric material of claim 13, wherein the crosslinker has a chain length of from about 5 to about 30 repeating Si units.
  • 15. The polymeric material of claim 13, wherein the crosslinker has a methyl-hydrogen content of from about 30 to about 70 mole %.
  • 16. An implantable intraocular lens (IOL) comprising the polymeric material of claim 1.
  • 17. A method of making the polymeric material of claim 1, comprising the steps of: (a) combining a vinyl end-capped fluorosilicone polymer with up to about 30 weight % of a silica component, wherein the silica component has a surface area of at least about 280 m2/g, to obtain a fluorosilicone base composition;(b) adding a crosslinking agent and a curing agent to the fluorosilicone base composition; and(c) curing the fluorosilicone base composition to obtain the polymeric material.
  • 18. An intraocular lens (IOL) device comprising: (a) a first lens comprising the polymeric material of claim 1 having a first Young's modulus;(b) a second lens in spaced relation to the first lens along a central optical axis; and(c) a circumferential portion encircling the first and second lens, the circumferential portion comprising an outer peripheral edge;wherein at least one of a portion of the second lens and a portion of the circumferential portion is made of a material having a second Young's modulus; andwherein the first Young's modulus is less than the second Young's modulus.
  • 19. A polymeric material comprising a crosslinked copolymer of dialkyl, diphenyl or phenylalkyl siloxane and fluorinated dialkyl siloxane, and up to about 30 weight % of a silica component, wherein the silica component has a surface area of at least about 280 m2/g, and wherein the polymeric material has a Young's modulus of from about 10 psi to about 150 psi.
  • 20. A polymeric material comprising a crosslinked copolymer of diphenyl, phenylalkyl, or dialkyl siloxane and trifluoroalkyl(alkyl)siloxane and up to about 30 weight % of a silica component, wherein the silica component has a surface area of at least about 280 m2/g, and wherein the polymeric material has a Young's modulus of from about 10 psi to about 150 psi.
  • 21. A polymeric material comprising a crosslinked terpolymer of diphenyl and/or phenylalkyl siloxane, dialkyl siloxane, and trifluoroalkyl(alkyl) siloxane, and up to about 30 weight % of a silica component, wherein the silica component has a surface area of at least about 280 m2/g, and wherein the polymeric material has a Young's modulus of from about 10 psi to about 150 psi.
PCT Information
Filing Document Filing Date Country Kind
PCT/US2015/051512 9/22/2015 WO 00
Publishing Document Publishing Date Country Kind
WO2016/049059 3/31/2016 WO A
US Referenced Citations (408)
Number Name Date Kind
4032502 Lee et al. Jun 1977 A
4373218 Schachar Feb 1983 A
4512040 McClure Apr 1985 A
4585457 Kalb Apr 1986 A
4720286 Bailey et al. Jan 1988 A
4731078 Stoy et al. Mar 1988 A
4822360 Deacon Apr 1989 A
4842601 Smith Jun 1989 A
4882368 Elias Nov 1989 A
4888012 Horn et al. Dec 1989 A
4892543 Turley Jan 1990 A
4932966 Christie et al. Jul 1990 A
5035710 Nakada et al. Jul 1991 A
5059668 Fukuda Oct 1991 A
5074876 Kelman Dec 1991 A
5091121 Nakada et al. Feb 1992 A
5152788 Isaacson et al. Oct 1992 A
5167883 Takemasa et al. Dec 1992 A
5171773 Chaffee et al. Dec 1992 A
5227447 Sato et al. Jul 1993 A
5236970 Christ et al. Aug 1993 A
5264522 Mize Nov 1993 A
5275623 Sarfarazi Jan 1994 A
5278258 Gerace Jan 1994 A
5312860 Mize et al. May 1994 A
5336487 Refojo et al. Aug 1994 A
5443506 Garabet Aug 1995 A
5447987 Sato Sep 1995 A
5489302 Skottun Feb 1996 A
5583178 Oxman et al. Dec 1996 A
5607472 Thompson Mar 1997 A
5665794 Maxson Sep 1997 A
5854310 Maxson Dec 1998 A
6071439 Bawa et al. Jun 2000 A
6117171 Skottun Sep 2000 A
6197057 Peyman et al. Mar 2001 B1
6361561 Huo et al. Mar 2002 B1
6551354 Ghazizadeh et al. Apr 2003 B1
6616691 Tran Sep 2003 B1
6695881 Peng et al. Feb 2004 B2
6730123 Klopotek May 2004 B1
6836374 Esch et al. Dec 2004 B2
6855164 Glazier Feb 2005 B2
6858040 Nguyen et al. Feb 2005 B2
6860601 Shadduck Mar 2005 B2
6926736 Peng et al. Aug 2005 B2
6930838 Schachar Aug 2005 B2
6935743 Shadduck Aug 2005 B2
6966649 Shadduck Nov 2005 B2
6969403 Peng et al. Nov 2005 B2
7041134 Nguyen et al. May 2006 B2
7063723 Ran Jun 2006 B2
7068439 Esch et al. Jun 2006 B2
7122053 Esch Oct 2006 B2
7150760 Zhang Dec 2006 B2
7217288 Esch et al. May 2007 B2
7220279 Nun May 2007 B2
7223288 Zhang et al. May 2007 B2
7226478 Ting et al. Jun 2007 B2
7229475 Glazier Jun 2007 B2
7238201 Portney et al. Jul 2007 B2
7247168 Esch et al. Jul 2007 B2
7261737 Esch et al. Aug 2007 B2
7264351 Shadduck Sep 2007 B2
7276619 Kunzler et al. Oct 2007 B2
7278739 Shadduck Oct 2007 B2
7316713 Zhang Jan 2008 B2
7416562 Gross Aug 2008 B2
7438723 Esch Oct 2008 B2
7452377 Watling Nov 2008 B2
7453646 Lo Nov 2008 B2
7485144 Esch Feb 2009 B2
7591849 Richardson Sep 2009 B2
7637947 Smith et al. Dec 2009 B2
7662179 Sarfarazi Feb 2010 B2
7675686 Lo et al. Mar 2010 B2
7753953 Yee Jul 2010 B1
7776088 Shadduck Aug 2010 B2
7780729 Nguyen et al. Aug 2010 B2
7815678 Nun Oct 2010 B2
7842087 Nun Nov 2010 B2
7854764 Nun Dec 2010 B2
7857850 Mentak et al. Dec 2010 B2
7981155 Cumming Jul 2011 B2
7985253 Cumming Jul 2011 B2
7986465 Lo et al. Jul 2011 B1
7998198 Angelopoulos et al. Aug 2011 B2
7998199 Nun Aug 2011 B2
8012204 Weinschenk, III et al. Sep 2011 B2
8018658 Lo Sep 2011 B2
8034106 Mentak et al. Oct 2011 B2
8034107 Stenger Oct 2011 B2
8038711 Clarke Oct 2011 B2
8048155 Shadduck Nov 2011 B2
8052752 Woods et al. Nov 2011 B2
8062361 Nguyen et al. Nov 2011 B2
8070806 Khoury Dec 2011 B2
8158712 Your Apr 2012 B2
8182531 Hermans et al. May 2012 B2
8187325 Zadno-Azizi et al. May 2012 B2
8197541 Schedler Jun 2012 B2
8216306 Coroneo Jul 2012 B2
8246679 Nguyen et al. Aug 2012 B2
8254034 Shields et al. Aug 2012 B1
8257827 Shi et al. Sep 2012 B1
8273123 Nun Sep 2012 B2
8303656 Shadduck Nov 2012 B2
8314927 Choi et al. Nov 2012 B2
8320049 Huang et al. Nov 2012 B2
8328869 Smiley et al. Dec 2012 B2
8361145 Scholl et al. Jan 2013 B2
8377124 Hong et al. Feb 2013 B2
8398709 Nun Mar 2013 B2
8414646 De Juan, Jr. et al. Apr 2013 B2
8425597 Glick et al. Apr 2013 B2
8425599 Shadduck Apr 2013 B2
8430928 Liao Apr 2013 B2
8447086 Hildebrand et al. May 2013 B2
8454688 Esch et al. Jun 2013 B2
8475529 Clarke Jul 2013 B2
8496701 Hermans et al. Jul 2013 B2
8500806 Phillips Aug 2013 B1
8545556 Woods et al. Oct 2013 B2
8579972 Rombach Nov 2013 B2
8585758 Woods Nov 2013 B2
8608799 Blake Dec 2013 B2
8608800 Portney Dec 2013 B2
8613766 Richardson et al. Dec 2013 B2
8647384 Lu Feb 2014 B2
8657878 Mentak et al. Feb 2014 B2
8668734 Hildebrand et al. Mar 2014 B2
8690942 Hildebrand et al. Mar 2014 B2
8715345 DeBoer et al. May 2014 B2
8715346 De Juan, Jr. et al. May 2014 B2
8734509 Mentak et al. May 2014 B2
8771347 DeBoer et al. Jul 2014 B2
8814934 Geraghty et al. Aug 2014 B2
8834565 Nun Sep 2014 B2
8858626 Noy Oct 2014 B2
8867141 Pugh et al. Oct 2014 B2
8900298 Anvar et al. Dec 2014 B2
8900300 Wortz Dec 2014 B1
8956408 Smiley et al. Feb 2015 B2
8968396 Matthews et al. Mar 2015 B2
8968399 Ghabra Mar 2015 B2
8992609 Shadduck Mar 2015 B2
9005282 Chang et al. Apr 2015 B2
9005283 Nguyen et al. Apr 2015 B2
9034035 Betser et al. May 2015 B2
9044317 Hildebrand et al. Jun 2015 B2
9072600 Tran Jul 2015 B2
9090033 Carson et al. Jul 2015 B2
9095424 Kahook et al. Aug 2015 B2
9125736 Kahook et al. Sep 2015 B2
9186244 Silvestrini et al. Nov 2015 B2
9198752 Woods Dec 2015 B2
9277987 Smiley et al. Mar 2016 B2
9289287 Kahook et al. Mar 2016 B2
9326846 Devita Gerardi et al. May 2016 B2
9333072 Ichikawa May 2016 B2
9358103 Wortz et al. Jun 2016 B1
9364316 Kahook et al. Jun 2016 B1
9387069 Kahook et al. Jul 2016 B2
9421088 Kahook et al. Aug 2016 B1
9427312 DeBoer et al. Aug 2016 B2
9433497 DeBoer et al. Sep 2016 B2
9456895 Shadduck Oct 2016 B2
9486311 Argento et al. Nov 2016 B2
9610155 Matthews Apr 2017 B2
9622852 Simonov et al. Apr 2017 B2
9629712 Stenger Apr 2017 B2
9636213 Brady May 2017 B2
9655716 Cumming May 2017 B2
9681946 Kahook et al. Jun 2017 B2
9693858 Hildebrand et al. Jul 2017 B2
9713526 Rombach Jul 2017 B2
9713527 Nishi et al. Jul 2017 B2
9717589 Simonov et al. Aug 2017 B2
9744027 Jansen Aug 2017 B2
9744028 Simonov et al. Aug 2017 B2
9795473 Smiley et al. Oct 2017 B2
9808339 Dorronsoro Diaz et al. Nov 2017 B2
9814568 Ben Nun Nov 2017 B2
9814570 Robert et al. Nov 2017 B2
9820849 Jansen Nov 2017 B2
9848980 McCafferty Dec 2017 B2
9855137 Smiley et al. Jan 2018 B2
9855139 Matthews et al. Jan 2018 B2
9861469 Simonov et al. Jan 2018 B2
9872762 Scholl et al. Jan 2018 B2
9872763 Smiley et al. Jan 2018 B2
9877825 Kahook et al. Jan 2018 B2
9883940 Nishi et al. Feb 2018 B2
9925039 Sohn et al. Mar 2018 B2
9925040 Kahook et al. Mar 2018 B2
9931202 Borja et al. Apr 2018 B2
9987126 Borja et al. Jun 2018 B2
10004596 Brady et al. Jun 2018 B2
10028824 Kahook et al. Jul 2018 B2
10045844 Smiley et al. Aug 2018 B2
10080648 Kahook et al. Sep 2018 B2
10111745 Silvestrini et al. Oct 2018 B2
10159564 Brady et al. Dec 2018 B2
10195018 Salahieh et al. Feb 2019 B2
10195020 Matthews Feb 2019 B2
20020005344 Heidlas et al. Jan 2002 A1
20020055776 Juan, Jr. et al. May 2002 A1
20020071856 Dillingham et al. Jun 2002 A1
20020120329 Lang et al. Aug 2002 A1
20030093149 Glazier May 2003 A1
20030105522 Glazier Jun 2003 A1
20030109926 Portney Jun 2003 A1
20030158295 Fukuda Aug 2003 A1
20040082993 Woods Apr 2004 A1
20040082994 Woods et al. Apr 2004 A1
20040111152 Kelman Jun 2004 A1
20040148023 Shu Jul 2004 A1
20040162612 Portney et al. Aug 2004 A1
20040169816 Esch Sep 2004 A1
20040249455 Tran Dec 2004 A1
20050021139 Shadduck Jan 2005 A1
20050071002 Glazier Mar 2005 A1
20050107873 Zhou May 2005 A1
20050137703 Chen Jun 2005 A1
20050251253 Gross Nov 2005 A1
20050251254 Brady et al. Nov 2005 A1
20050267575 Nguyen et al. Dec 2005 A1
20060041307 Esch et al. Feb 2006 A1
20060047339 Brown Mar 2006 A1
20060069178 Rastogi et al. Mar 2006 A1
20060074487 Gilg Apr 2006 A1
20060111776 Glick et al. May 2006 A1
20060134173 Liu et al. Jun 2006 A1
20060135477 Haitjema et al. Jun 2006 A1
20060212116 Woods Sep 2006 A1
20060238702 Glick et al. Oct 2006 A1
20060241752 Israel Oct 2006 A1
20070016293 Tran Jan 2007 A1
20070032868 Woods et al. Feb 2007 A1
20070050024 Zhang Mar 2007 A1
20070050025 Nguyen et al. Mar 2007 A1
20070078515 Brady et al. Apr 2007 A1
20070088433 Esch et al. Apr 2007 A1
20070100445 Shadduck May 2007 A1
20070106377 Smith et al. May 2007 A1
20070118216 Pynson May 2007 A1
20070129798 Chawdhary Jun 2007 A1
20070129799 Schedler Jun 2007 A1
20070129800 Cumming Jun 2007 A1
20070129801 Cumming Jun 2007 A1
20070132949 Phelan Jun 2007 A1
20070213817 Esch et al. Sep 2007 A1
20070260308 Tran Nov 2007 A1
20070260310 Richardson Nov 2007 A1
20080015689 Esch et al. Jan 2008 A1
20080033547 Chang et al. Feb 2008 A1
20080046074 Smith et al. Feb 2008 A1
20080046075 Esch et al. Feb 2008 A1
20080046077 Cumming Feb 2008 A1
20080051886 Lin Feb 2008 A1
20080154364 Richardson et al. Jun 2008 A1
20080200982 Your Aug 2008 A1
20080269887 Cumming Oct 2008 A1
20080300680 Nun Dec 2008 A1
20080306587 Your Dec 2008 A1
20080306588 Smiley et al. Dec 2008 A1
20080306589 Donitzky et al. Dec 2008 A1
20090005865 Smiley et al. Jan 2009 A1
20090027661 Choi et al. Jan 2009 A1
20090043384 Niwa et al. Feb 2009 A1
20090116118 Frazier et al. May 2009 A1
20090125106 Weinschenk, III et al. May 2009 A1
20090149952 Shadduck Jun 2009 A1
20090198326 Zhou et al. Aug 2009 A1
20090204209 Tran Aug 2009 A1
20090204210 Pynson Aug 2009 A1
20090264998 Mentak et al. Oct 2009 A1
20090292355 Boyd et al. Nov 2009 A1
20090319040 Khoury Dec 2009 A1
20100004742 Cumming Jan 2010 A1
20100055449 Ota Mar 2010 A1
20100057095 Khuray et al. Mar 2010 A1
20100094412 Wensrich Apr 2010 A1
20100094413 Rombach et al. Apr 2010 A1
20100131058 Shadduck May 2010 A1
20100179653 Argento et al. Jul 2010 A1
20100204787 Noy Aug 2010 A1
20100211169 Stanley et al. Aug 2010 A1
20100228344 Shadduck Sep 2010 A1
20100288346 Esch Sep 2010 A1
20100324672 Esch et al. Dec 2010 A1
20100324674 Brown Dec 2010 A1
20110029074 Reisin et al. Feb 2011 A1
20110071628 Gross et al. Mar 2011 A1
20110118834 Lo et al. May 2011 A1
20110118836 Jain May 2011 A1
20110224788 Webb Sep 2011 A1
20110282442 Scholl et al. Nov 2011 A1
20110288638 Smiley et al. Nov 2011 A1
20120016473 Brady et al. Jan 2012 A1
20120035724 Clarke Feb 2012 A1
20120071972 Zhao Mar 2012 A1
20120078364 Stenger Mar 2012 A1
20120095125 Hu et al. Apr 2012 A1
20120232649 Cuevas Sep 2012 A1
20120245683 Christie et al. Sep 2012 A1
20120253458 Geraghty et al. Oct 2012 A1
20120253459 Reich et al. Oct 2012 A1
20120290084 Coroneo Nov 2012 A1
20120296423 Caffey Nov 2012 A1
20120296424 Betser Nov 2012 A1
20120310341 Simonov et al. Dec 2012 A1
20120310343 Van Noy Dec 2012 A1
20130006353 Betser et al. Jan 2013 A1
20130035760 Portney Feb 2013 A1
20130038944 Chang et al. Feb 2013 A1
20130060331 Shadduck Mar 2013 A1
20130110234 DeVita et al. May 2013 A1
20130110235 Shweigerling May 2013 A1
20130116781 Nun May 2013 A1
20130131794 Smiley et al. May 2013 A1
20130190867 Peyman Jul 2013 A1
20130231741 Clarke Sep 2013 A1
20130250239 Hildebrand et al. Sep 2013 A1
20130268070 Esch et al. Oct 2013 A1
20130297018 Brady et al. Nov 2013 A1
20130317607 DeBoer et al. Nov 2013 A1
20130317608 Hermans et al. Nov 2013 A1
20140012277 Matthews et al. Jan 2014 A1
20140058507 Reich et al. Feb 2014 A1
20140085726 Portney Mar 2014 A1
20140100654 Portney et al. Apr 2014 A1
20140107459 Lind et al. Apr 2014 A1
20140111765 DeBoer et al. Apr 2014 A1
20140121768 Simpson May 2014 A1
20140135917 Glazier May 2014 A1
20140135918 De Juan, Jr. et al. May 2014 A1
20140172092 Carson et al. Jun 2014 A1
20140180404 Tram Jun 2014 A1
20140180405 Weinschenk, III et al. Jun 2014 A1
20140180406 Simpson Jun 2014 A1
20140180407 Sohn et al. Jun 2014 A1
20140180410 Gerardi Jun 2014 A1
20140227437 DeBoer Aug 2014 A1
20140228949 Argento et al. Aug 2014 A1
20140249625 Shadduck Sep 2014 A1
20140257478 McCafferty Sep 2014 A1
20140257479 McCafferty Sep 2014 A1
20140309734 Sohn et al. Oct 2014 A1
20150087743 Anvar et al. Mar 2015 A1
20150105760 Rao et al. Apr 2015 A1
20150127102 Wortz May 2015 A1
20150173892 Borja et al. Jun 2015 A1
20150202041 Shadduck Jul 2015 A1
20150216652 Jansen Aug 2015 A1
20150238310 Matthews et al. Aug 2015 A1
20150366656 Wortz et al. Dec 2015 A1
20160000558 Honigsbaum Jan 2016 A1
20160008126 Salahieh et al. Jan 2016 A1
20160051361 Phillips Feb 2016 A1
20160058553 Salahieh et al. Mar 2016 A1
20160074154 Woods Mar 2016 A1
20160184089 Dudee et al. Jun 2016 A1
20160184092 Smiley et al. Jun 2016 A1
20160208138 Nishijima Jul 2016 A1
20160256265 Borja et al. Sep 2016 A1
20160262875 Smith et al. Sep 2016 A1
20160281019 Deklippel Sep 2016 A1
20160287380 Shi et al. Oct 2016 A1
20160317287 Silvestrini et al. Nov 2016 A1
20170020662 Shadduck Jan 2017 A1
20170049561 Smiley et al. Feb 2017 A1
20170049562 Argento et al. Feb 2017 A1
20170216021 Brady Aug 2017 A1
20170290658 Hildebrand et al. Oct 2017 A1
20170319332 Kahook et al. Nov 2017 A1
20170342096 Silvestrini Nov 2017 A1
20170348095 Wortz et al. Dec 2017 A1
20180014928 Kahook et al. Jan 2018 A1
20180028308 Smiley et al. Feb 2018 A1
20180110613 Wortz et al. Apr 2018 A1
20180125640 Smiley et al. May 2018 A1
20180132997 Smiley et al. May 2018 A1
20180147051 Scholl et al. May 2018 A1
20180153682 Hajela et al. Jun 2018 A1
20180161152 Argento et al. Jun 2018 A1
20180161153 Kahook et al. Jun 2018 A1
20180177589 Argento et al. Jun 2018 A1
20180177639 Rao et al. Jun 2018 A1
20180256315 Hildebrand et al. Sep 2018 A1
20180271642 Wortz et al. Sep 2018 A1
20180271645 Brady et al. Sep 2018 A1
20180280135 Otts Oct 2018 A1
20180296323 Olcina Portilla Oct 2018 A1
20180307061 State et al. Oct 2018 A1
20180318068 Otts et al. Nov 2018 A1
20180344453 Brady Dec 2018 A1
20180368971 Zacher et al. Dec 2018 A1
20180368973 Wortz et al. Dec 2018 A1
20180368974 Kahook et al. Dec 2018 A1
20190000612 Rao et al. Jan 2019 A1
20190015198 Kuiper Jan 2019 A1
20190021848 Kahook et al. Jan 2019 A1
20190069989 Otts et al. Mar 2019 A1
20190076239 Wortz et al. Mar 2019 A1
20190076243 Hadba et al. Mar 2019 A1
20190083235 Wortz Mar 2019 A1
20190099263 Brady et al. Apr 2019 A1
Foreign Referenced Citations (61)
Number Date Country
0356050 Feb 1990 EP
0766540 Aug 1999 EP
H09-150002 Jun 1997 JP
2013-047290 Mar 2013 JP
WO 9217132 Oct 1992 WO
WO 9929266 Jun 1999 WO
WO 2001034067 May 2001 WO
WO 2004037127 May 2004 WO
WO 2004052242 Jun 2004 WO
WO 2004054471 Jul 2004 WO
WO 2004072689 Aug 2004 WO
WO 2006047383 May 2006 WO
WO 2007005778 Jan 2007 WO
WO 2007047529 Apr 2007 WO
WO 2007047530 Apr 2007 WO
WO 2008024766 Feb 2008 WO
WO 2008031231 Mar 2008 WO
WO 2008077040 Jun 2008 WO
WO 2008082957 Jul 2008 WO
WO 2008103798 Aug 2008 WO
WO 2009015161 Jan 2009 WO
WO 2009015226 Jan 2009 WO
WO 2009015234 Jan 2009 WO
WO 2009015240 Jan 2009 WO
WO 2009064876 May 2009 WO
WO 2010010565 Jan 2010 WO
WO 2010081093 Jul 2010 WO
WO 2011026068 Mar 2011 WO
WO 2011106435 Sep 2011 WO
WO 2011137191 Nov 2011 WO
WO 2012006616 Jan 2012 WO
WO 2012129407 Sep 2012 WO
WO 2013016804 Feb 2013 WO
WO 2013070924 May 2013 WO
WO 2013142323 Sep 2013 WO
WO 2013166068 Nov 2013 WO
WO 2013190130 Dec 2013 WO
WO-2013180254 Dec 2013 WO
WO 2014099630 Jun 2014 WO
WO 2014145562 Sep 2014 WO
WO 2014152017 Sep 2014 WO
WO 2014197170 Dec 2014 WO
WO 2015066502 May 2015 WO
WO 2015066532 May 2015 WO
WO 2015126604 Aug 2015 WO
WO 2016018932 Feb 2016 WO
WO 2016033217 Mar 2016 WO
WO 2016122805 Aug 2016 WO
WO 2016201351 Dec 2016 WO
WO 2017079449 May 2017 WO
WO 2017079733 May 2017 WO
WO 2017087358 May 2017 WO
WO 2017096087 Jun 2017 WO
WO 2017192855 Nov 2017 WO
WO 2018081595 May 2018 WO
WO 2018119408 Jun 2018 WO
WO 2018167099 Sep 2018 WO
WO 2018222579 Dec 2018 WO
WO 2018227014 Dec 2018 WO
WO 2019005859 Jan 2019 WO
WO 2019027845 Feb 2019 WO
Non-Patent Literature Citations (13)
Entry
International Preliminary Report on Patentability for International Application No. PCT/US2015/051512 dated Mar. 28, 2017. (7 pages).
Extended European Search Report for European Application No. 15844326.7 dated Apr. 26, 2018. (10 pages).
International Search Report and Written Opinion for PCT/US2015/051512 dated Jan. 13, 2016, 12 pages.
Pubchem, Substance Record for SID 184590955, Deposit Date: Jun. 23, 2014 (retrieved Dec. 28, 2015). Retrieved from the Internet: <URL: https://pubchem.ncbi.nlm.nih.gov/substance/184590955#section=Top>.
Ehrmann, et al., “Biomechanical analysis of the accommodative apparatus in primates”, Clinical and Experimental Optometry, May 2008, vol. 91, Issue 3, pp. 302-312.
Ehrmann, et al., “Ex Vivo Accommodation Simulator II—Concept and Preliminary Results”, Proceedings of SPIE vol. 5314, Ophthalmic Technologies XIV, Jul. 2004, pp. 48-58.
Gabel, et al., “Silicone oil with high specific gravity for intraocular use”, British Journal of Ophthalmology, Apr. 1987, vol. 71, 262-267.
Ghallagher-Wetmore, et al., “Supercritical fluid processing: a new dry technique for photoresist developing”, SPIE's 1995 Symposium on Microlithography, 1995, vol. 2438, 16 pages.
Lane, et al., “Comparison of the biomechanical behavior of foldable intraocular lenses” Journal of Cataract Refract Surg, Nov. 2004, vol. 30, 2397-2402.
Nakamura, et al., “Analysis and Fractionation of Silicone and Fluorosilicone Oils for Intraocular Use”, Investigative Ophthalmology & Visual Science, vol. 31, No. 10, Oct. 1990, 2059-2069.
Zhang, et al., “Fluidic adaptive lens with high focal length tunability”, Applied Physics Letters, May 2003, vol. 82, No. 19, pp. 3171-3172.
Zhang, et al., “Integrated fluidic adaptive zoom lens”, Optics Letters, Dec. 2004, vol. 29, No. 24, pp. 2855-2857.
Zhao, et al., “Strategies for Supercritical CO2 Fractionation of Polydimethylsiloxane,” Journal of Applied Polymer Science, 1995, vol. 55, 773-778.
Related Publications (1)
Number Date Country
20170247525 A1 Aug 2017 US
Provisional Applications (1)
Number Date Country
62054303 Sep 2014 US